<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714242</url>
  </required_header>
  <id_info>
    <org_study_id>1401/21</org_study_id>
    <nct_id>NCT04714242</nct_id>
  </id_info>
  <brief_title>OCTA and Polypoidal Choroidal Vasculopathy</brief_title>
  <official_title>Choroid and Choriocapillary Changes in Polypoidal Choroidal Vasculopathy After Intravitreal Anti-VEGF Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the structural and vascular features of choroid in patients affected by PCV&#xD;
      after Ranibizumab intravitreal injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polypoidal choroidal vasculopathy represents a distinct form of choroidal neovascularization.&#xD;
&#xD;
      The study investigated the changes in choroidal vascular network after anti-VEGF therapy&#xD;
      using optical coherence tomography angiography, a novel and non invasive diagnostic technique&#xD;
      that allows to better understand the pathophysiologic mechanism of this neovascularization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Actual">December 20, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of vascular features of choroid in polypoidal choroidal vasculopathy after intravitreal injections of Ranibizumab</measure>
    <time_frame>12 Months</time_frame>
    <description>The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography angiography. The parameters analyzed by optical coherence tomography angiography were: choriocapillaris vessel density.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of structural features of choroid in polypoidal choroidal vasculopathy after intravitreal</measure>
    <time_frame>12 Months</time_frame>
    <description>The effectiveness of Ranibizumab injections for treating PCV using optical optical coherence tomography. The parameters analyzed by optical coherence tomography were: subfoveal choroidal thickness.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Patients underwent anti-VEGF therapy</arm_group_label>
    <description>intravitreal Anti-VEGF therapy: Three monthly intravitreal injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy eyes without actual and previous ocular diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection</intervention_name>
    <description>Three monthly intravitreal injections of Ranibizumab</description>
    <arm_group_label>Patients underwent anti-VEGF therapy</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 60 years with diagnosis of polypoidal choroidal&#xD;
        vasculopathy They did not present other ophthalmological diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 60 years&#xD;
&#xD;
          -  diagnosis of polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  absence of previous ocular surgery, congenital eye disease, high myopia (&gt;6 dioptres),&#xD;
             actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal&#xD;
             diseases.&#xD;
&#xD;
          -  absence of significant lens opacities, low-quality OCT-A images.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age older than 80 years&#xD;
&#xD;
          -  absence of diagnosis of polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  presence of previous ocular surgery, congenital eye disease, high myopia (&gt;6&#xD;
             dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or&#xD;
             vitreoretinal diseases.&#xD;
&#xD;
          -  presence of significant lens opacities, low-quality OCT-A images.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gilda Cennamo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

